{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:57Z","timestamp":1791471777650,"version":"4.3.4"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This is the first report on the effects of abrocitinib, a Janus kinase 1\u2013selective inhibitor, on the expression of skin biomarkers in patients with moderate\u2010to\u2010severe atopic dermatitis (AD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>JADE MOA (NCT03915496) was a double\u2010blind Phase 2a trial. Adults were randomly assigned 1:1:1 to receive monotherapy with once\u2010daily abrocitinib 200\u2009mg, abrocitinib 100\u2009mg, or placebo for 12\u2009weeks. The primary endpoint was change from baseline in markers of inflammation (matrix metalloproteinase [MMP]\u201012), epidermal hyperplasia (keratin\u201016 [KRT16]), T\u2010helper 2 (Th2) immune response (C\u2010C motif chemokine ligand [CCL]17, CCL18, and CCL26), and Th22 immune response (S100 calcium binding protein A8, A9, and A12 [S100A8, S100A9, and S100A12]) in skin through 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 46 patients received abrocitinib 200\u2009mg (<jats:italic>n<\/jats:italic>\u2009=\u200914), abrocitinib 100\u2009mg (<jats:italic>n<\/jats:italic>\u2009=\u200916), or placebo (<jats:italic>n<\/jats:italic>\u2009=\u200916). Abrocitinib improved AD clinical signs and reduced itch. Gene expression of <jats:italic>MMP\u201012<\/jats:italic>, <jats:italic>KRT16<\/jats:italic>, <jats:italic>S100A8<\/jats:italic>, <jats:italic>S100A9<\/jats:italic>, and <jats:italic>S100A12<\/jats:italic> was significantly decreased from baseline with abrocitinib 200\u2009mg (at Weeks 2, 4, and 12) and abrocitinib 100\u2009mg (at Weeks 4 and 12) in a dose\u2010dependent manner. Abrocitinib 200\u2009mg resulted in significant decreases from baseline in <jats:italic>CCL17<\/jats:italic> expression at Week 12 and <jats:italic>CCL18<\/jats:italic> expression at Weeks 2, 4, and 12; no significant decreases were observed for <jats:italic>CCL26<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Alongside improvements in clinical signs and symptoms of AD, 12\u2009weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate\u2010to\u2010severe AD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/all.15969","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T10:14:18Z","timestamp":1702894458000},"page":"1258-1270","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effect of abrocitinib on skin biomarkers in patients with moderate\u2010to\u2010severe atopic dermatitis"],"prefix":"10.1111","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman\u2010Yassky","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jesus","family":"Gomez\u2010Arias","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del\u00a0Duca","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Correa","family":"Da\u00a0Rosa","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders Hospital Saint\u2010Andr\u00e9  Bordeaux France"},{"name":"Bordeaux University, CNRS UMR 5164, Immunoconcept  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[{"name":"University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel D.","family":"Estrada","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaroop N.","family":"Bose","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allshine","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tatulych","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"G\u00fcler","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Page","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Kerkmann","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.032"},{"key":"e_1_2_11_5_1","unstructured":"Cibinqo (abrocitinib).Prescribing information. Pfizer Labs;2022."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01199-0"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01598"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2010.06.004"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144316"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12967"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.039"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.06.047"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.041"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19040"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.10.005"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911546"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.001"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.040"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14490"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.048"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.08.024"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.016"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.04.023"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.013"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052684"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe2749"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020239"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13491"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4176"},{"key":"e_1_2_11_39_1","first-page":"37","article-title":"Interleukin\u201022 and keratinocytes; pathogenic implications in skin inflammation","volume":"1","author":"Furue M","year":"2021","journal-title":"Explor Immunol"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1723"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.03.006"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.041"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.047"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113741"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00115.x"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000110"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.07.013"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042116"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T10:56:43Z","timestamp":1720695403000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/all.15969"],"URL":"https:\/\/doi.org\/10.1111\/all.15969","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"2023-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}